Oxford AZ vaccine
India approves Oxford vaccine
India’s Central Drugs Standard Control Organization (CDSCO)
Rollout to start Wednesday
UK
Argentina
India
What about Europe and the US?
Europe, 400 million does
US, 300 million doses
On different topic
Oxford AstraZeneca $ per dose
Pfizer, $20
Moderna, $ to $38 per dose
Where is rollout going well
Israel, 644,000 or 7% so far
Bahrain
UK
US
Canada
Europe
Oxford/AstraZeneca vaccine
Phase 2 trials
56-day gap
Phase 3 trials
(20)32623-4/fulltext
Good immunity with 6-week gap
(20)32661-1/fulltext
Efficacy after one dose, 64%
Efficacy after 2 doses, 70 – 80%
Cases, 21 days after first SD, 64%
Vaccine group, 51
Control group, 141
Efficacy 64%
Severe cases 21 days after the first dose of Oxford / AZ
Vaccine group, 0
Control group, 10 hospitalised (2 severe, 1 death)
Covid-19: Pfizer BioNTech vaccine efficacy was 52% after first dose and 95% after second dose
Twelve days after the first dose
Vaccine group, 39 cases
Placebo group, 82 cases
52% efficacy
Severe cases after one dose
Vaccine group, 1
Placebo group, 9
New UK vaccine protocol
Change to one dose, second within 3 months
Statement from the UK Chief Medical Officers on the prioritisation of first doses of COVID-19 vaccines
Medicines and Healthcare products Regulatory Agency (MHRA)
Oxford, 2 doses 4 to 12 weeks apart
Pfizer, 2 doses 3 to 12 weeks apart
The Joint Committee on Vaccination and Immunisation (JCVI)
will protect the greatest number of at risk people overall
in the shortest possible time
and will have the greatest impact on reducing mortality,
severe disease
and hospitalisations
and in protecting the NHS and equivalent health services.
second doses of both vaccines will be administered towards the end of the recommended vaccine dosing schedule of 12 weeks
The Green Book
If an interval longer than the recommended interval is left between doses, the second dose should still be given
(preferably using the same vaccine as was given for the first dose).
The course does not need to be restarted.
There is no evidence on the interchangeability of the COVID-19 vaccines although studies are underway.
Therefore, every effort should be made to determine which vaccine the individual received and to complete with the same vaccine.
There is no evidence of any safety concerns from vaccinating individuals with a past history of COVID-19 infection, or with detectable COVID-19 antibody.
India approves Oxford vaccine
India’s Central Drugs Standard Control Organization (CDSCO)
Rollout to start Wednesday
UK
Argentina
India
What about Europe and the US?
Europe, 400 million does
US, 300 million doses
On different topic
Oxford AstraZeneca $ per dose
Pfizer, $20
Moderna, $ to $38 per dose
Where is rollout going well
Israel, 644,000 or 7% so far
Bahrain
UK
US
Canada
Europe
Oxford/AstraZeneca vaccine
Phase 2 trials
56-day gap
Phase 3 trials
(20)32623-4/fulltext
Good immunity with 6-week gap
(20)32661-1/fulltext
Efficacy after one dose, 64%
Efficacy after 2 doses, 70 – 80%
Cases, 21 days after first SD, 64%
Vaccine group, 51
Control group, 141
Efficacy 64%
Severe cases 21 days after the first dose of Oxford / AZ
Vaccine group, 0
Control group, 10 hospitalised (2 severe, 1 death)
Covid-19: Pfizer BioNTech vaccine efficacy was 52% after first dose and 95% after second dose
Twelve days after the first dose
Vaccine group, 39 cases
Placebo group, 82 cases
52% efficacy
Severe cases after one dose
Vaccine group, 1
Placebo group, 9
New UK vaccine protocol
Change to one dose, second within 3 months
Statement from the UK Chief Medical Officers on the prioritisation of first doses of COVID-19 vaccines
Medicines and Healthcare products Regulatory Agency (MHRA)
Oxford, 2 doses 4 to 12 weeks apart
Pfizer, 2 doses 3 to 12 weeks apart
The Joint Committee on Vaccination and Immunisation (JCVI)
will protect the greatest number of at risk people overall
in the shortest possible time
and will have the greatest impact on reducing mortality,
severe disease
and hospitalisations
and in protecting the NHS and equivalent health services.
second doses of both vaccines will be administered towards the end of the recommended vaccine dosing schedule of 12 weeks
The Green Book
If an interval longer than the recommended interval is left between doses, the second dose should still be given
(preferably using the same vaccine as was given for the first dose).
The course does not need to be restarted.
There is no evidence on the interchangeability of the COVID-19 vaccines although studies are underway.
Therefore, every effort should be made to determine which vaccine the individual received and to complete with the same vaccine.
There is no evidence of any safety concerns from vaccinating individuals with a past history of COVID-19 infection, or with detectable COVID-19 antibody.
- Категория
- Мировое кино

Комментариев нет.